- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02939612
Stress Management Intervention in Early Stage Cancer: Randomized Controlled Trial
Testing a Computerized Interactive Stress Management Intervention in Early Stage Cancer: a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A cancer diagnosis and subsequent treatment can be disruptive and traumatic, often accompanied by a multitude of stressors for the patients and their support network. Uncertainty of outcome and invasive medical procedures with aversive side effects are not uncommon, and while people differ widely in how they experience and cope with such challenges, cancer related distress including anxiety, depression, worry and rumination is prevalent. With multiple domains of function impacted it is also not surprising that quality of life (QoL) often is diminished.
Stress management interventions can facilitate adjustment to cancer, including reduced distress and improved quality of life. Unfortunately, many people with cancer do not have the strength or opportunity to attend groups or in-person interventions.
This study will therefore test the effect of an app for stress management among patients with different cancer diagnosis. The app contains 10 modules distributed over five weeks, focusing on education of different techniques for reduction of stress and stress reduction exercises.
The app was tested in a feasibility pilot study among 25 patients with a variety of cancer diagnoses and is now being tested in a randomized controlled trial with a sample of 175 cancer survivors. The participants were randomly assigned to use the 10 module app or to a control group that receive treatment as usual, and will be followed with repeated measures over 12 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Oslo, Norway
- Oslo University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients diagnosed with cancer (all diagnosis).
- Maximum time since completed treatment at hospital: 12 months
- Patients are > 18 years of age, able to write/read/speak Norwegian and have their own smart phone or tablet
Exclusion Criteria:
• None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: App for Stress management
Participants will get access to two modules per week for five weeks (total 10 modules).
The app consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
|
An app consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
Other Names:
|
|
No Intervention: Waitlist control group
Participants will get treatment as usual during the study.
After the one year study follow up they will receive the stress management app.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Perceived Stress Scale (PSS-14)
Time Frame: Baseline, post intervention follow up at 3, 6, and 12 months
|
14 item scale measuring perceived stress.
Scale range: 0-56.
Higher scores indicate higher perceived stress.
|
Baseline, post intervention follow up at 3, 6, and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SF-36 Item Short Form Health Survey (RAND-36 version)
Time Frame: Baseline, post intervention follow up at 3, 6, and 12 months
|
36 item scale measuring health related quality of life (HRQoL).
The scale has 8 subscales and 1 single item score.
Scale and single item range: 0 to 100.
Higher scores indicate higher HRQoL.
|
Baseline, post intervention follow up at 3, 6, and 12 months
|
|
The Self-Regulatory Fatigue-18 (SRF-18)
Time Frame: Baseline, post intervention follow up at 3 and 12 months
|
18 item scale measuring self-regulation.
Scale range: 18 to 90.
A higher score indicates higher self regulatory fatigue
|
Baseline, post intervention follow up at 3 and 12 months
|
|
The Brief Coping Orientation to Problems (Brief COPE)
Time Frame: Baseline
|
The outcome measure consists of 14 different scales of different coping strategies with two items per scale, for a total of 28 items.
Scale range 2 to 8. Higher scores indicate higer use of the different coping strategies
|
Baseline
|
|
Health, well-being and sleep
Time Frame: Baseline, post intervention follow up at 3, 6, and 12 months
|
A 5 item measure, measuring health, well-being and sleep on a scale from 0 to 10. Higher scores indicate better health, well-being and sleep
|
Baseline, post intervention follow up at 3, 6, and 12 months
|
|
Intervention commentary
Time Frame: Post intervention (immediately post intervention)
|
A six item brief measure of participant's intervention reactions.
The first 3 items gauged participants' program perception on a scale from 1 to 5, with 5 indicating better perception.
The next 3 items were open ended questions: * What did you like best?
* What did you like the least?
* Suggestions for improvement?
|
Post intervention (immediately post intervention)
|
|
The Hospital Anxiety and Depression Scale (HADS)
Time Frame: Baseline, post intervention follow up at 3, 6, and 12 months
|
14 item scale measuring anxiety and depression.
The Scale has a total score with a scale range of 0 to 42 and an anxiety (HADS-A) and a depression (HADS-D) subscale, both with scale range of 0 to 21. Higer scores indicate higher level of anxiety and depression
|
Baseline, post intervention follow up at 3, 6, and 12 months
|
|
The Distress Thermometer
Time Frame: Baseline, post intervention follow up at 3, 6, and 12 months
|
One item scale measuring distress on a scale from 0 to 10. Higer scores indicate higher distress
|
Baseline, post intervention follow up at 3, 6, and 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lise Solberg Nes, PhD, Oslo University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016/1436
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.